View all press releases

Tetra Bio-Pharma’s Clinical Research Partner, Altasciences, offers Innovative Cannabis Research Solutions


Ottawa, Ontario - (August 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and Altasciences are pleased to share that they are in the final stages of completing the world’s first safety and tolerability study on a cannabis extract being developed as a new chemical entity for approval by the FDA and Health Canada as a drug.

Starting in January 2017, Altasciences combined their decades of experience designing and conducting studies on cannabinoid-based products, products delivered by inhalation, and testing of products that are smoked, to design and conduct with Tetra Bio-Pharma the world’s first safety and tolerability study on a cannabis extract smoked using a specialized delivery device being developed as a new chemical entity for regulatory approval as a drug.

“The sponsor, Tetra Bio-Pharma, approached us with the desire to conduct a first-in-human test on their product, a cannabis extract that is formed into a pellet and smoked in a specialized titanium pipe. The pellet had been designed to provide consistent dosing in a format that was easy to transport and deliver. The study was designed to test whether the format met the criteria and to establish the safety of the product and device. Innovation is at the core of how we design and conduct clinical studies at Altasciences,” explained Dr. Graham Wood, Executive Vice President, Phase I Development, at Altasciences.

“We are proud to have found in Altasciences a world-class partner in running our PPP-001 clinical program. Our association is an important factor in our ability to efficiently move through our Phase I clinical trial and we are expecting our Phase III clinical, which is on target to start in Q4 of 2017, to be run as efficiently with Altasciences once again as its key partner,” stated Bernard Fortier, CEO of Tetra Bio-Pharma.

Altasciences implemented a smoking technique to minimize variability, and used their well-ventilated specialized smoking rooms to prevent cross-contamination between active and placebo participants. Also, with their 20,000-square-foot bioanalytical laboratory a few kilometers away from their clinic, Altasciences was able to very quickly measure the blood levels of the active ingredients and their metabolites. Finally, Altasciences used iPad-based cognitive assessments and subjective measures of the psychoactive effects to monitor if the subjects were impaired. Together, this enabled us to very quickly collect the data to make the safety decisions for the dose escalation.

If you are interested in learning more, Dr. Marc Lefebvre, Vice President, Scientific and Regulatory Affairs, at Altasciences, will be presenting the details of this innovative study at the Partnerships in Clinical Trials Europe event in Amsterdam, on November 28, 2017. Dr. Graham Wood will also be providing insight during his presentation at the BioPharma Forum on Cannabis-Based Science & Medicine in Denver, Colorado, from November 30 to December 1, 2017

Altasciences is currently working with Tetra Bio-Pharma on their future studies for the cannabis extract as well as planning for studies on their second cannabis-based product that will be ready for first-in-human studies this fall.

About Altasciences:

Altasciences Clinical Research encompasses Algorithme Pharma in Montreal, Quebec, Vince & Associates Clinical Research in Overland Park, KS, as well as Algorithme Pharma USA in Fargo, ND, thereby making it one of the largest early phase clinical CROs in North America. With over 25 years of industry experience, Altasciences provides early phase clinical development services to an international customer base of biopharmaceutical and generic companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes medical writing, biostatistics, data management and bioanalysis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. More information is available about the company at:

Source: Tetra Bio-Pharma

For further information, please contact Tetra Bio-Pharma Inc.

Edward Miller

Vice President, IR & Corporate Communications

(514) 360-8040 Ext. 203

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Categories: Press Releases
View all press releases